2010 Scrip 100 - Argentina biotech: time to invest?
This article was originally published in Scrip
Argentinian firms have a surprising amount of expertise in the field of biosimilars, while a strong science base has fed healthy demand for locally manufactured products. Can the country elevate its early-stage research efforts to the next level without big pharma's dollars? Francesca Bruce investigates.